Tango Therapeutics saw the highest growth of 1.99% in patent filings and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Tango Therapeutics’s patent filings and grants. Buy the databook here.
Tango Therapeutics has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 100% grants. The United States(US), Australia(AU), Israel(IL), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Tango Therapeutics is filings its patents. Among the top granted patent authorities, Tango Therapeutics has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Tango Therapeutics
Patents related to rare diseases lead Tango Therapeutics's portfolio
Tango Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Esophageal cancer related patents lead Tango Therapeutics portfolio followed by leukemia, and pancreatic cancer
Tango Therapeutics has highest number of patents in esophageal cancer followed by leukemia, pancreatic cancer, non-small cell lung cancer, and bladder carcinoma. For esophageal cancer, nearly 2% of patents were filed and 6% of patents were granted in Q2 2024.
For comprehensive analysis of Tango Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.